Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. The Company has operations in pharmaceutical, animal health, and consumer care.
Website: merck.com


  • Good financial results growth rate 26.7% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (9.1%)
  • Dividend yield for the last twelve months 3.8%
  • Free cash flow yield 0.2% (LTM)
  • Share price is 17.4% higher than minimum and 35.1% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (9.1x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.7 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: MRK
Share price, USD:  (+0.6%)86.28
year average price 87.33  


year start price 102.92 2024-11-10

max close price 103.79 2024-12-09

min close price 73.47 2025-05-14

current price 86.28 2025-11-09
Common stocks: 2 528 810 012

Dividend Yield:  3.8%
FCF Yield LTM: 0.2%
EV / LTM EBITDA: 9.1x
EV / EBITDA annualized: 7.6x
Last revenue growth (y/y):  +3.7%
Last growth of EBITDA (y/y):  +49.7%
Historical revenue growth:  +3.0%
Historical growth of EBITDA:  +15.2%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 218 186
Net Debt ($m): 23 217
EV (Enterprise Value): 241 403
EBITDA LTM ($m): 26 386
EV / LTM EBITDA: 9.1x
Price to Book: 4.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-03businesswire.com

Merck Foundation Launches $22 Million Initiative to Improve Cardiovascular Care in the U.S.

2025-10-30zacks.com

MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down

2025-10-30seekingalpha.com

Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript

2025-10-30wsj.com

Merck Profit Rises on Strong Keytruda Demand

2025-10-30cnbc.com

Merck tops estimates on Keytruda strength and narrows profit outlook, as it lowers estimated tariff hit

2025-10-30reuters.com

Merck posts higher third-quarter sales as Keytruda growth offsets drop from Gardasil

2025-10-30businesswire.com

Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

2025-10-28zacks.com

Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know

2025-10-27zacks.com

Are You Looking for a High-Growth Dividend Stock?

2025-10-24seekingalpha.com

Merck Q3 Earnings Preview: Issues That Will Dominate The Agenda
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data